Codagenix utilizes our breakthrough platform technology termed SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method developed in the 1880s, pre-dating the discovery of the DNA double helix. Codagenix presents a breakthrough approach to live-attenuated vaccine design. The SAVE platform instead relies on synthetic biology and the rational "re-design" of a target virus' entire genome to yield a vaccine strain. This customization process uses software-based algorithms to 're-code' the genome of a target virus. SAVE-'re-coding' results in a vaccine virus with proteins 100% identical to the target strain, ensuring the best possible antigenic match, but possesses a genome that renders it attenuated in the host. SAVE is an up-stream approach to vaccine construction. The science behind the SAVE 're-design' targets a fundamental process of all viruses and thus it is viewed as platform that will yield a pipeline of candidate vaccine strains against multiple targets that include: Influenza virus, Dengue Virus, Respiratory Syncytial virus, poliovirus, and others.
Location: United States, New York, Farmingdale
Employees: 11-50
Total raised: $47M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Adjuvant C... | adjuvantca... |
| 15.04.2022 | In-Q-Tel | iqt.org |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.02.2023 | Series B | $25M | Adjuvant C... |
| 13.01.2020 | Series B | $20M | - |
| 12.06.2015 | Series A | $2M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.02.2023 | Codagenix Closes $25M Extension of Series B | Farmingdale, NY, Codagenix closed a $25M in series B funding led with participation from a new investor, the Serum Institute of India Pvt. >> Click here for more funding data on Codagenix >> To export Codagenix funding data ... |
| 15.02.2023 | Codagenix Raises $25M in Series B Extension Funding | Codagenix, a Farmingdale, New York-based clinical-stage synthetic biology company, raised $25M in Series B Extension funding. The round was led by Serum Institute of India with participation from existing investors Euclidean Capital and Adj... |
| 09.01.2023 | COVID-19 vaccines: From nasal drops to a redesign, what 2023 could have in store | Several vaccine companies say they are expecting breakthroughs as early as this year as they pursue new ways to protect people against SARS-CoV-2, the virus that causes COVID-19. The Food and Drug Administration is set to convene a panel of... |
| 22.09.2021 | Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies | FARMINGDALE, N.Y., Sept. 22, 2021 /PRNewswire/ -- Codagenix Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced that their novel intranasal COVI-VAC vaccine ha... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands. Curr... |
| 13.01.2020 | Codagenix Raises $20 Million in Series B | Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the closing of a $20 million Series B investment round. The new investment was led by Adjuvant Capital, ... |
| 13.01.2020 | Daily funding roundup - January 13th, 2020 | SimpliField raised $11M; Naïo Technologies landed $15.5M; Codagenix secured $20M New Age Meats: New Age Meats a meat from animal cells. New Age Meats has raised $2.7 million in seed round funding led by ff Venture Capital. Other investors i... |
| 13.01.2020 | Codagenix Raises $20M in Series B Funding | Codagenix, Inc., a Farmngdale, N.Y.-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, closed a $20m Series B funding round. The round was led by Adjuvant Capital, with participation f... |
| 13.01.2020 | Codagenix raises $20M Series B for continued development of viruses for use as vaccines or solid tumor therapies | Codagenix, is a clinical stage biotechnology startup with vaccine products against influenza, respiratory syncytial virus, dengue virus, has closed $20 million Series B investment round. The round was led by Adjuvant Capital, with participa... |
Show more